A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer
19 de mayo de 2026 actualizado por: Changchun GeneScience Pharmaceutical Co., Ltd.
An Multi-center, Open-label Phase Ib/II Study of Gentuximab Injection + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer to Evaluate Tolerability, Safety, Efficacy and Pharmacokinetics.
The objective of the study is to evaluate Tolerability, Safety, and primary Efficacy of Gentuximab Injection at different dosage in combination with Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer patients, to ensure adequate treatment dosage for further study.
Meanwhile, the study also evaluate Pharmacokinetics of Gentuximab Injection at different dosage in combination with Paclitaxel.
Descripción general del estudio
Estado
Estado
Terminado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
The study includes dose-limiting toxicity （DLT）observing period and randomization period with two cohorts as low-dose group（Gentuximab Injection 8mg/kg+ paclitaxel） and high-dose group（Gentuximab Injection 12mg/kg+ paclitaxel）.
During the study，the anti-cancer efficacy, safety and anti-drug antibody were evaluated in all patients.
DLT observation is only to subjects enrolled in DLT observation period and it lasts one treatment period.
PK were doing in part of subjects.
Tipo de estudio
Tipo de estudio
Intervencionista
Inscripción (Actual)
Inscripción
76
Fase
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
Estudio Contacto
- Nombre: Siqin Wang
- Correo electrónico: wangsiqin@gensci-china.com
Copia de seguridad de contactos de estudio
- Nombre: Jin Li
- Número de teléfono: 13761222111
- Correo electrónico: tianyoulijin@163.com
Ubicaciones de estudio
-
-
-
Shanghai, Porcelana
- Shanghai First People's Hospital
-
Shanghai, Porcelana
- Shanghai East Hospital
-
-
Fujian
-
Fuzhou, Fujian, Porcelana
- Fujian Tumor Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, Porcelana
- The Sixth Hospital of Sun Yat-sen University
-
-
Heilongjiang
-
Harbin, Heilongjiang, Porcelana
- The Affiliated Tumor Hospital of Harbin Medical University
-
-
Henan
-
Zhengzhou, Henan, Porcelana
- The First Affiliated Hospital of Zhengzhou University
-
-
Hubei
-
Wuhan, Hubei, Porcelana
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
-
-
Jiangsu
-
Nanjing, Jiangsu, Porcelana
- Jiangsu Province Hospital
-
-
Jilin
-
Changchun, Jilin, Porcelana
- The First Hospital of Jilin University
-
-
Zhejiang
-
Hangzhou, Zhejiang, Porcelana
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Hangzhou, Zhejiang, Porcelana
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
-
Hangzhou, Zhejiang, Porcelana
- Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 75 años (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Descripción
Inclusion Criteria:
- The subject can understand the process and methods of the study, complete the study in accordance with the protocol and is willing to sign a written informed consent.
- Male or female. aged between 18 and 75 years
- Histopathologically confirmed advanced advanced gastric or gastroesophageal junction cancer, and Documented progression during first-line fluoropyrimidine- and platinum- containing chemotherapy, or during the 3 months following the last cycle of such chemotherapy (or during the 6 months following the last dose of adjuvant therapy or new adjuvant therapy containing fluoropyrimidine and platinium).
- At least one Measurable lesion.
- ECOG Performance status (PS) score, 0-1 level.
- A life expectancy of >3 months.
- Adequate hematologic function, as defined by: Absolute neutrophil count (ANC) ≥1.5×109/L; hemoglobin concentration ≥90g/L (allowing blood transfusion); and platelet count ≥80×109/L.
- Adequate hepatic function, as defined by: ALT ≤ 2.5 × ULN, AST ≤ 2.5 × ULN, TBIL ≤ 1.5 × ULN (liver metastases patients ALT ≤ 5 × ULN, AST ≤ 5 × ULN, TBIL ≤ 3 × ULN).
- Adequate renal function, as defined by: serum creatinine level≤ 1.5 × ULN, or creatinine clearance ≥ 50ml / min when serum creatinine level> 1.5 × ULN.
- Adequate coagulation function, as defined by: International normalized ratio (INR) ≤1.5× ULN, activated partial thromboplastin time (aPTT) ≤1.5 x ULN.
- 24-hour urine protein quantitation is <1g（24-hour urine protein quantitative test should be performed when urine protein ≥1+ is found during screening visit）.
- Subjects (male and female) who have fertility must agree to use reliable contraceptive methods during the trial and in 3 months after the last administration. Female subjects in childbearing age must be negative for blood pregnancy test prior to enrollment.
Exclusion Criteria:
- Previously administrated with anti-angiogenic drugs or paclitaxel.
- Systematic anti-tumor therapy (non-anti-angiogenic drugs or paclitaxel) such as chemotherapy, radiotherapy, macromolecular targeted therapy, immunotherapy, endocrine therapy, etc. within 4 weeks before the first dose of investigational drug, except for the following: nitrourea or mitomycin C is within 6 weeks before the first dose, oral fluorouracil and small molecule targeted drugs are within 2 weeks or 5 half-life of the drug(whichever is longer) before the first dose，Chinese medicine with anti-cancer indications is within 2 weeks before the first dose.
- Has participated in a clinical study of a non-approved experimental agent within 4 weeks prior to screening visit.
- Has undergone major surgery within 4 weeks before screening visit (not including needle biopsy)， or would undergo planned surgery during the study.
- Subject with positive HCV-Ab, Anti-HIV or TP-Ab, or positive HBS-Ag with copies of HBV DNA > ULN.
- Patients with previously confirmed malignant tumors.
- History of arterial thrombosis or deep vein thrombosis within 6 months prior to screening, or a bleeding event no less than Grade level 3 within 2 months prior to screening， or the investigator determines that there is a risk of bleeding.
- History of severe cardiovascular and cerebrovascular diseases.
- Subjects with confirmed brain tumor metastases，but subjects in steady situation can be enrolled.
- Active bleeding confirmed by gastroscopy when fecal occult blood positive (only subjects with primary lesions not removed need to do fecal occult blood test.
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 12 months before screening visit.
- Thoracic，abdominal or pericardial effusion that cannot be controlled by repeated drainage or with obvious symptoms.
- Has a nonhealing wound, serious ulcer, or unrecovered bone fracture.
- Active infections requiring systemic treatment, including but not limited to active tuberculosis.
- Using anticoagulation and antiplatelet drugs.
- Female subjects who is pregnant (confirmed by urine or serum pregnancy test) or lactating.
- Has a known serious allergy reaction to recombination monoclonal antibody (MAb) drug, ,or infusion reaction.
- Has known alcohol or drug dependency.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
2
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: 1 Gentuximab+ Paclitaxel
8 mg/kg Gentuximab administered intravenously (IV) on D1 and D15（28 days every cycle）+ 80 mg/m² paclitaxel administered IV on D1, D8 and D15
|
Administered intravenously (IV)
Administrado por vía intravenosa (iv)
|
|
Experimental: 2 Gentuximab+ Paclitaxel
12 mg/kg Gentuximab administered intravenously (IV) on D1 and D15（28 days every cycle）+ 80 mg/m² paclitaxel administered IV on D1, D8 and D15
|
Administered intravenously (IV)
Administrado por vía intravenosa (iv)
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Dose-limiting toxicities (DLT)
Periodo de tiempo: Up to 4 Weeks
|
Number of Participants With One or More Drug-Related Adverse Events (AEs) defined as DLT in the protocol
|
Up to 4 Weeks
|
|
AEs or SAEs
Periodo de tiempo: Baseline through Study Completion, about 24 weeks
|
Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs)
|
Baseline through Study Completion, about 24 weeks
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Objective response rate（ORR）
Periodo de tiempo: Up to 6 cycles (28 days for every cycle)
|
Proportion of Participants With CR and PR
|
Up to 6 cycles (28 days for every cycle)
|
|
Progression-free survival (PFS)
Periodo de tiempo: Up to 6 cycles (28 days for every cycle)
|
The time from randomization to the patient tumor progression or death.
|
Up to 6 cycles (28 days for every cycle)
|
|
Disease control rate (DCR)
Periodo de tiempo: Up to 6 cycles (28 days for every cycle)
|
Proportion of Participants With CR, PR and SD
|
Up to 6 cycles (28 days for every cycle)
|
|
Time-to-progress (TTP)
Periodo de tiempo: Up to 6 cycles (28 days for every cycle)
|
The time from randomization to the patient tumor progression.
|
Up to 6 cycles (28 days for every cycle)
|
|
Time-to-failure (TTF)
Periodo de tiempo: Up to 6 cycles (28 days for every cycle)
|
The time from randomization to the patient withdraw from the study.
|
Up to 6 cycles (28 days for every cycle)
|
|
Anti-drug antibody
Periodo de tiempo: Up to 6 cycles (28 days for every cycle)
|
Number of Participants With Anti-drug Antibodies
|
Up to 6 cycles (28 days for every cycle)
|
|
Pharmacokinetics Cmax
Periodo de tiempo: Cycle 1(day1-day 15)& Cycle 2(day 15-day26) & Cycle 3(day 1) (28 days for every cycle)
|
Maximum Concentration (Cmax)
|
Cycle 1(day1-day 15)& Cycle 2(day 15-day26) & Cycle 3(day 1) (28 days for every cycle)
|
|
Area Under the Concentration-Time Curve (AUC)
Periodo de tiempo: Cycle 1(day1-day 15)& Cycle 2(day 15-day26) & Cycle 3(day 1) Cycle 1(day1-day 15)& Cycle 2(day 15-day26) & Cycle 3(day 1) （28 days for every cycle）
|
Cycle 1(day1-day 15)& Cycle 2(day 15-day26) & Cycle 3(day 1) Cycle 1(day1-day 15)& Cycle 2(day 15-day26) & Cycle 3(day 1) （28 days for every cycle）
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
5 de noviembre de 2019
Finalización primaria (Actual)
Finalización primaria
1 de junio de 2020
Finalización del estudio (Actual)
Finalización del estudio
20 de septiembre de 2020
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
27 de julio de 2019
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
9 de agosto de 2019
Publicado por primera vez (Actual)
Publicado por primera vez
12 de agosto de 2019
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
22 de mayo de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
19 de mayo de 2026
Última verificación
Última verificación
1 de mayo de 2026
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- GenSci 043 CT
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .